Neurotech International (ASX:NTI) - Aktienkurs, Nachrichten und Analyse

NTI Aktienübersicht

Neurotech International Limited ist zusammen mit seinen Tochtergesellschaften in der Forschung, dem Design, der Entwicklung und der Herstellung von medizinischen Geräten und Lösungen in Australien tätig.

Über das Unternehmen

NTI grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	0/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	6/6
Dividenden	0/6

Belohnungen

Risikoanalyse

Die Erträge sind in den letzten 5 Jahren um 10.5% pro Jahr zurückgegangen

Die Aktionäre wurden im vergangenen Jahr verwässert

Hat keine nennenswerten Einnahmen (A$3M)

Hat keine nennenswerte Marktkapitalisierung (A$75M)

Neurotech International Limited Wettbewerber

Micro-X

ASX:MX1

AU$48.2m

Austco Healthcare

ASX:AHC

AU$64.9m

EMVision Medical Devices

ASX:EMV

AU$184.5m

Compumedics

ASX:CMP

AU$59.3m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Neurotech International
Historische Aktienkurse
Aktueller Aktienkurs	AU$0.07
52-Wochen-Hoch	AU$0.13
52-Wochen-Tief	AU$0.037
Beta	1.64
11 Monat Veränderung	-2.78%
3 Monate Veränderung	-36.36%
1 Jahr Veränderung	75.00%
33 Jahre Veränderung	32.08%
5 Jahre Veränderung	250.00%
Veränderung seit IPO	-75.44%

Aktuelle Nachrichten und Updates

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

Jan 28

Recent updates

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

Jan 28

We Think Neurotech International (ASX:NTI) Needs To Drive Business Growth Carefully

Oct 14

Here's Why We're Not Too Worried About Neurotech International's (ASX:NTI) Cash Burn Situation

Jul 01

Is Neurotech International (ASX:NTI) In A Good Position To Invest In Growth?

Jan 21

Is Neurotech International (ASX:NTI) In A Good Position To Deliver On Growth Plans?

Oct 06

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

May 18

We're Not Very Worried About Neurotech International's (ASX:NTI) Cash Burn Rate

Dec 21

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Sep 04

Need To Know: Neurotech International Limited (ASX:NTI) Insiders Have Been Selling Shares

Dec 08

Aktionärsrenditen

	NTI	AU Medical Equipment	AU Markt
7D	4.5%	2.0%	-0.3%
1Y	75.0%	26.3%	8.3%

Rendite im Vergleich zur Industrie: NTI übertraf die Branche Australian Medical Equipment , die im vergangenen Jahr eine Rendite von 21.5 erzielte.

Rendite vs. Markt: NTI übertraf den Markt Australian, der im vergangenen Jahr eine Rendite von 6.2 erzielte.

Preisvolatilität

Is NTI's price volatile compared to industry and market?
NTI volatility
NTI Average Weekly Movement	8.7%
Medical Equipment Industry Average Movement	9.4%
Market Average Movement	8.2%
10% most volatile stocks in AU Market	16.3%
10% least volatile stocks in AU Market	3.2%

Stabiler Aktienkurs: NTIDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: NTIDie wöchentliche Volatilität (9%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2016	n/a	Peter James Griffiths	www.neurotechinternational.com

Neurotech International Limited ist zusammen mit seinen Tochtergesellschaften in der Forschung, Konzeption, Entwicklung und Herstellung von medizinischen Geräten und Lösungen in Australien tätig. Das Unternehmen konzentriert sich auf die Entwicklung und Vermarktung der Mente-Plattform, einer Plattformtechnologie zur Überwachung und Unterstützung von Therapien im häuslichen Umfeld. Zu seinen Produkten gehört Mente Autism für die Diagnose und Behandlung von Autismus.

Neurotech International Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Neurotech International im Vergleich zum Marktanteil des Unternehmens?
NTI grundlegende Statistiken
Marktanteil	AU$71.22m
Gewinn(TTM)	-AU$4.98m
Umsatz(TTM)	AU$3.20m

22.2x

Kurs-Umsatz-Verhältnis

-14.3x

Kurs-Gewinn-Verhältnis

Ist NTI zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
NTI Gewinn- und Verlustrechnung (TTM)
Einnahmen	AU$3.20m
Kosten der Einnahmen	AU$28.87k
Bruttogewinn	AU$3.18m
Sonstige Ausgaben	AU$8.16m
Umsatz	-AU$4.98m

Zuletzt gemeldete Gewinne

Dec 31, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.0049
Bruttomarge	99.10%
Nettogewinnspanne	-155.47%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich NTI auf lange Sicht entwickelt?

Historische Performance und Vergleiche

NTI Aktienübersicht

Belohnungen

Risikoanalyse

Neurotech International Limited Wettbewerber

ASX:MX1

AU$48.2m

ASX:AHC

AU$64.9m

ASX:EMV

AU$184.5m

ASX:CMP

AU$59.3m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Less than half of directors are independent

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

Independent Non-Executive Director exercised options to buy AU$114k worth of stock.

Neurotech International Limited to Report Q1, 2024 Results on Oct 27, 2023

Recent updates

Less than half of directors are independent

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

Independent Non-Executive Director exercised options to buy AU$114k worth of stock.

Neurotech International Limited to Report Q1, 2024 Results on Oct 27, 2023

Neurotech International Limited, Annual General Meeting, Nov 15, 2023

We Think Neurotech International (ASX:NTI) Needs To Drive Business Growth Carefully

Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

Neurotech International Limited to Report Q4, 2023 Results on Jul 26, 2023

New minor risk - Share price stability

Here's Why We're Not Too Worried About Neurotech International's (ASX:NTI) Cash Burn Situation

First half 2023 earnings released: AU$0.48 loss per share (vs AU$0.003 loss in 1H 2022)

Neurotech International Limited Announces First Patient Treated in Phase I/II PANDAS/PANS Trial

Neurotech International Limited Announces Approval for Additional Phase I/II ASD Trial Extension

Neurotech International Limited Receives HREC Approval for Phase I/II PANDAS/PANS Clinical Trial

Neurotech International Limited to Report Q3, 2023 Results on Jan 30, 2023

Is Neurotech International (ASX:NTI) In A Good Position To Invest In Growth?

Neurotech International Limited Announces Grant of FDA Pre-IND Meeting for NTI164 in ASD

Neurotech International Limited Announces Passing of Professor Allan Cripps AO, Non-Executive Director

Neurotech International Limited Announces Commencement of Patient Randomisation and First Patient Successfully Treats Under New Phase II/III NTIASD2 Clinical Trial for Children with Autism Spectrum Disorder

Less than half of directors are independent

Neurotech International Limited, Annual General Meeting, Nov 30, 2022

Neurotech International Limited, Annual General Meeting, Nov 23, 2022

Neurotech International Limited Reports Further Significant Clinical Improvement at 20 Weeks for Paediatric Autism Patients Treated with NTI164

Neurotech International Limited Announces New Phase I/II Clinical Trial in Children with PANDAS/PANS

Is Neurotech International (ASX:NTI) In A Good Position To Deliver On Growth Plans?

Neurotech International Limited Provides Autism Spectrum Disorder Phase I/II Clinical Trial Update

Less than half of directors are independent

Neurotech International Limited Announces Transition of Alexandra Andrews from Chief Executive Officer to a New Position of Chief Operating Officer

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.015 loss in FY 2021)

Neurotech International Limited Announces Currently Finalising a Pivotal Phase II/III Clinical Trial Design to be Conducted in Australia

Neurotech International ORDINARY FULLY PAID to Be Deleted from OTC Equity

Neurotech International Limited Announces Executive Changes

Neurotech International Limited Announces Results with NTI164 in Paediatric ASD

High number of new directors

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

Neurotech International Limited Announces Important Developments Relating to the Study Protocol Assessing NTI164 in Children with Autism Spectrum Disorder

High number of new directors

Neurotech International Limited Announces Successful Developments Relating to Safety and Tolerability of NTI164 and Key Behavioural Parameters That Impact Autism Spectrum Disorder Patients

Neurotech International Limited Appoints Alexandra Andrews as Chief Executive Officer, Effective 8 March 2022

We're Not Very Worried About Neurotech International's (ASX:NTI) Cash Burn Rate

Neurotech International Limited Announces Nti164 Clinical Program Update

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Full year 2021 earnings released: AU$0.015 loss per share (vs AU$0.011 loss in FY 2020)

Neurotech International Limited Announces the Continuation of Its Pre-Clinical Program in Neuro-Inflammatory Disease Models In-Line with Research and Development Pathway

Neurotech International Limited Initiates Phase I/II Open Label Study into Autism

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2 million.

Neurotech International Limited Announces Strategic Cultivation Partnership with CannaPacific Limited

Neurotech International Limited Announces the Expansion of Its Exclusive License with Dolce Cann Global Pty Ltd

Neurotech International Limited Provides an Update on Clinical Study Program

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Need To Know: Neurotech International Limited (ASX:NTI) Insiders Have Been Selling Shares

Neurotech International Limited Announces Initiation of Clinical Product Formulation Studies

Neurotech International Limited Announces Transition of Peter Griffiths as CEO

Neurotech International Limited Commences Landmark in Vitro Trials of Unique Cannabis Strains

Full year earnings released - AU$0.011 loss per share

Aktionärsrenditen

Erträge & Einnahmen